Skip to Main Content

Paper Details

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
J Clin Oncol
167
2015
Author NameAffiliation
Ramona F SwabyCentre Hospitalier Universitaire, Petrov Research Institute of Oncology, Franciszek Lukaszczyk Oncology Center, The Royal Wolverhampton Hospitals National Health Service Trust, Nottingham University Hospital, "Regina Elena" National Cancer Institute, Hospital Universitario 12 de Octubre, Karolinska University Hospital, Collegeville
  • 1 - 1

Datasets

Release 1.2